Hongbin Yi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hongbin Yi has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Sheng Han
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China
5 shared publications Liping Kuai
Science and Technology Development Center, Chinese Pharmaceutical Association, Beijing, China
4 shared publications- Xiaoxia Wei
Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China
4 shared publications Dongyan Xu
Science and Technology Development Centre, Chinese Pharmaceutical Association, Beijing, China
3 shared publications- Yingdan Cao
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China
3 shared publications - Fenghao Shi
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (2) , e002633
Association of haematological cancer drugs recommendation levels in Chinese Society of Clinical Oncology guideline with different approval approaches: a cross-sectional study
Introduction: To evaluate the associations between approval approaches and the Chinese Society of Clinical Oncology (CSCO) guidelines for haematological cancer drug indications. Methods: Haematological cancer drug indications approved via different approaches between 2015 and 2023 were retrieved from the National Medical Products Administration (NMPA) website, and their CSCO guideline recommendation levels were analysed. Basic characteristics were analysed descriptively. Fisher’s test and t-tests were used to respectively explore the associations of the approval approaches and the recommendation level, and the time difference between the indications obtaining the recommendation level and being approved by the NMPA. Changes in recommendation levels were also analysed. Results: The NMPA approved 52 haematological cancer drug indications (33 anticancer drugs) from 2015 to 2023. 5 indications were approved via routine approval (RA) and 47 were approved via accelerated approval (AA). 39 indications obtained CSCO guideline recommendation level I. Indications approved via the AA and RA were similarly likely to obtain level I. The average time for the indications approved via the RA to obtain the recommendation level is 7.6 months before the indications were approved by the NMPA. And the average time for the indications approved via AA to obtain the recommended level is −5.51 months. For indications approved via priority review and RA, there was a difference in the average time from obtaining recommendation level to obtaining NMPA approval. Compared with CSCO’s initial recommendation levels, 15 indications obtained higher recommendation level in the updated CSCO guideline. Conclusions: Most haematological cancer drug indications obtained CSCO guideline recommendation level I, with no significant difference between AA and RA in the recommendation level. Indications approved via RA obtained recommendation level more quickly. Some indications obtained a higher recommendation level in the updated guideline. Strengthening communication between the NMPA and CSCO and ensuring timely integration of emerging evidence may improve the alignment between approval decisions and recommendation level.
- 1 April 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (2) , e002633
Open AccessAssociation of haematological cancer drugs recommendation levels in Chinese Society of Clinical Oncology guideline with different approval approaches: a cross-sectional study
Introduction: To evaluate the associations between approval approaches and the Chinese Society of Clinical Oncology (CSCO) guidelines for haematological cancer drug indications. Methods: Haematological cancer drug indications approved via different approaches between 2015 and 2023 were retrieved from the National Medical Products Administration (NMPA) website, and their CSCO guideline recommendation levels were analysed. Basic characteristics were analysed descriptively. Fisher’s test and t-tests were used to respectively explore the associations of the approval approaches and the recommendation level, and the time difference between the indications obtaining the recommendation level and being approved by the NMPA. Changes in recommendation levels were also analysed. Results: The NMPA approved 52 haematological cancer drug indications (33 anticancer drugs) from 2015 to 2023. 5 indications were approved via routine approval (RA) and 47 were approved via accelerated approval (AA). 39 indications obtained CSCO guideline recommendation level I. Indications approved via the AA and RA were similarly likely to obtain level I. The average time for the indications approved via the RA to obtain the recommendation level is 7.6 months before the indications were approved by the NMPA. And the average time for the indications approved via AA to obtain the recommended level is −5.51 months. For indications approved via priority review and RA, there was a difference in the average time from obtaining recommendation level to obtaining NMPA approval. Compared with CSCO’s initial recommendation levels, 15 indications obtained higher recommendation level in the updated CSCO guideline. Conclusions: Most haematological cancer drug indications obtained CSCO guideline recommendation level I, with no significant difference between AA and RA in the recommendation level. Indications approved via RA obtained recommendation level more quickly. Some indications obtained a higher recommendation level in the updated guideline. Strengthening communication between the NMPA and CSCO and ensuring timely integration of emerging evidence may improve the alignment between approval decisions and recommendation level.
- Open Access
- 1 April 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (2) , e004332
Impacts of national volume-based procurement policy on insulin price, volume and expenditure in China: a quasi-experimental study
Introduction: To alleviate the diabetes economic burden, the Chinese government implemented the national volume-based procurement (NVBP) policy exclusively for insulin in May 2022. However, there is limited evidence on the impact of NVBP policy on insulin procurement prices, volumes and expenditures. Methods: We conducted an interrupted time series analysis (ITSA) to evaluate the policy’s impacts on insulin procurement prices, volumes and expenditure. Quarterly data for 15 insulins were extracted from the China Medicine Economic Information database, covering 761 public hospitals in 30 provinces from Q3 2020 to Q4 2023. The intervention time of the ITSA model is Q2 2022. Insulin prices are measured using the defined daily dose (DDD) cost, while the volumes are measured using DDDs. Results: Following the NVBP implementation, all NVBP bid-winning insulin prices decreased by 51.61%, volume increased by 16.73% and expenditure decreased by 43.52%. All NVBP bid-winning insulin volumes increased by 9152.73 thousand DDDs and showed an upward trend (p<0.05). The expenditure decreased by 176.65 million Chinese yuan (CNY) (p<0.05). The prices of all six NVBP insulin groups decreased significantly, and the prices of the three NVBP insulin groups showed a downward trend (p<0.05). The volumes of all six NVBP insulin groups showed significant increases in either level or trend. Except for premixed human insulin analogues, expenditure significantly changed in level or trend in the remaining five groups (p<0.05). Individually, all 15 insulins exhibited significant price reductions, while 10 of them also showed significant increases in both volumes and expenditures. Conclusions: China’s NVBP policy exclusively for insulin significantly reduced prices, increased overall volumes and lowered expenditures. These changes indicate that this policy enhances insulin utilisation and affordability, providing evidence for centralised procurement’s effectiveness in mitigating diabetes-related economic burden.
- 1 April 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (2) , e004332
Open AccessImpacts of national volume-based procurement policy on insulin price, volume and expenditure in China: a quasi-experimental study
Introduction: To alleviate the diabetes economic burden, the Chinese government implemented the national volume-based procurement (NVBP) policy exclusively for insulin in May 2022. However, there is limited evidence on the impact of NVBP policy on insulin procurement prices, volumes and expenditures. Methods: We conducted an interrupted time series analysis (ITSA) to evaluate the policy’s impacts on insulin procurement prices, volumes and expenditure. Quarterly data for 15 insulins were extracted from the China Medicine Economic Information database, covering 761 public hospitals in 30 provinces from Q3 2020 to Q4 2023. The intervention time of the ITSA model is Q2 2022. Insulin prices are measured using the defined daily dose (DDD) cost, while the volumes are measured using DDDs. Results: Following the NVBP implementation, all NVBP bid-winning insulin prices decreased by 51.61%, volume increased by 16.73% and expenditure decreased by 43.52%. All NVBP bid-winning insulin volumes increased by 9152.73 thousand DDDs and showed an upward trend (p<0.05). The expenditure decreased by 176.65 million Chinese yuan (CNY) (p<0.05). The prices of all six NVBP insulin groups decreased significantly, and the prices of the three NVBP insulin groups showed a downward trend (p<0.05). The volumes of all six NVBP insulin groups showed significant increases in either level or trend. Except for premixed human insulin analogues, expenditure significantly changed in level or trend in the remaining five groups (p<0.05). Individually, all 15 insulins exhibited significant price reductions, while 10 of them also showed significant increases in both volumes and expenditures. Conclusions: China’s NVBP policy exclusively for insulin significantly reduced prices, increased overall volumes and lowered expenditures. These changes indicate that this policy enhances insulin utilisation and affordability, providing evidence for centralised procurement’s effectiveness in mitigating diabetes-related economic burden.
- Open Access
- 6 March 2026
- Published by International Society of Global Health in Journal of Global Health
- Vol. 16, 04078
The effect of diagnosis-related group policy on treatment cost and treatment efficiency of inpatients with coronary heart disease in Xinjiang: an interrupted time series analysis
Rapid increases in health care costs and unequal distribution of medical resources have become pervasive challenges for health systems globally in recent years [1]. Payment models based on diagnosis-related groups (DRGs) have emerged as possible solutions and have been adopted across numerous developed nations and regions [2,3]. By classifying inpatient episodes into standardised groups […]
- 6 March 2026
- Published by International Society of Global Health in Journal of Global Health
- Vol. 16, 04078
Open AccessThe effect of diagnosis-related group policy on treatment cost and treatment efficiency of inpatients with coronary heart disease in Xinjiang: an interrupted time series analysis
Rapid increases in health care costs and unequal distribution of medical resources have become pervasive challenges for health systems globally in recent years [1]. Payment models based on diagnosis-related groups (DRGs) have emerged as possible solutions and have been adopted across numerous developed nations and regions [2,3]. By classifying inpatient episodes into standardised groups […]
- Open Access
- 18 April 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04069
Evaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis
Cancer is a global problem that lacks a global solution [1]. A study indicated that there were 19.3 million new cases of cancer and almost 10 million deaths from cancer in 2020. Cancer is a significant cause of morbidity and mortality worldwide, across all regions and at all levels of human development [2]. Harnessing the […]
- 18 April 2025
- Published by International Society of Global Health in Journal of Global Health
- Vol. 15, 04069
Open AccessEvaluation of changes in price, volume and expenditure of PD-1 drugs following the government reimbursement negotiation in China: a multiple-treatment period interrupted time series analysis
Cancer is a global problem that lacks a global solution [1]. A study indicated that there were 19.3 million new cases of cancer and almost 10 million deaths from cancer in 2020. Cancer is a significant cause of morbidity and mortality worldwide, across all regions and at all levels of human development [2]. Harnessing the […]
- 1 October 2024
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 46 (6) , 1427-1435
Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion–positive non-small cell lung cancer in the United States
Background Although selpercatinib has shown clinical benefits for rearranged during transfection (RET) fusion–positive non-small cell lung cancer (NSCLC), its cost-effectiveness requires further evaluation. Aim This study aimed to evaluate the cost-effectiveness of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of RET fusion–positive NSCLC from the perspective of the United States (US) payer. Method A partitioned survival model was developed based on data from the LIBRETTO-431 trial. Cost and utility values for the health state were obtained from database data or published literature. The measured outcomes included quality-adjusted life-years (QALYs) and the incremental cost-effectiveness ratio (ICER). One-way sensitivity analysis and probabilistic sensitivity analyses (PSA) were conducted to assess the uncertainty of the model. Results Selpercatinib increased QALYs in patients with RET fusion–positive NSCLC by 0.90 compared to chemotherapy plus pembrolizumab, with an additional cost of $542,517.45, resulting in an ICER of $603,286.49/QALY, which exceeded the willingness-to-pay (WTP) threshold ($150,000) in the US. One-way sensitivity analysis suggested that the utility of progressed disease, the utility of progression-free survival, the price of selpercatinib, the discount, the price of pemetrexed, and the price of pembrolizumab had the greatest influence on the cost- effectiveness analysis process. In the PSA, 99.9% of the scatter points were distributed above the US WTP threshold of $150,000. Conclusion From the perspective of the US payer, selpercatinib is not cost-effective compared to chemotherapy and pembrolizumab for first-line treatment in patients with RET fusion-positive NSCLC.
- 1 October 2024
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 46 (6) , 1427-1435
Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion–positive non-small cell lung cancer in the United States
Background Although selpercatinib has shown clinical benefits for rearranged during transfection (RET) fusion–positive non-small cell lung cancer (NSCLC), its cost-effectiveness requires further evaluation. Aim This study aimed to evaluate the cost-effectiveness of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of RET fusion–positive NSCLC from the perspective of the United States (US) payer. Method A partitioned survival model was developed based on data from the LIBRETTO-431 trial. Cost and utility values for the health state were obtained from database data or published literature. The measured outcomes included quality-adjusted life-years (QALYs) and the incremental cost-effectiveness ratio (ICER). One-way sensitivity analysis and probabilistic sensitivity analyses (PSA) were conducted to assess the uncertainty of the model. Results Selpercatinib increased QALYs in patients with RET fusion–positive NSCLC by 0.90 compared to chemotherapy plus pembrolizumab, with an additional cost of $542,517.45, resulting in an ICER of $603,286.49/QALY, which exceeded the willingness-to-pay (WTP) threshold ($150,000) in the US. One-way sensitivity analysis suggested that the utility of progressed disease, the utility of progression-free survival, the price of selpercatinib, the discount, the price of pemetrexed, and the price of pembrolizumab had the greatest influence on the cost- effectiveness analysis process. In the PSA, 99.9% of the scatter points were distributed above the US WTP threshold of $150,000. Conclusion From the perspective of the US payer, selpercatinib is not cost-effective compared to chemotherapy and pembrolizumab for first-line treatment in patients with RET fusion-positive NSCLC.
- 11 July 2024
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 46 (6) , 1335-1344
Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States
Background Although amivantamab has shown clinical benefits for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertions, its cost-effectiveness requires further investigation. Aim To evaluate the cost-effectiveness of amivantamab plus chemotherapy for the treatment of NSCLC patients with EGFR exon 20 insertions from the United States payer perspective. Method A partitioned survival model was developed based on the data from the PAPILLON trial. Costs were derived from the pricing files of Medicare and Medicaid Services and published literature, and utility values were derived from previous studies. A 3% annual discount rate was applied to both costs and outcomes. The primary outcome was the incremental cost-effectiveness ratio (ICER). One-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis, were conducted to test the model stability. Results Amivantamab plus chemotherapy yielded an additional 1.12 quality-adjusted life years (QALYs) while increasing costs by $483,769.50 relative to the chemotherapy regimen, leading to an ICER of $432,401.16/QALY. The combination of amivantamab with chemotherapy was not cost effective at a threshold of $150,000/QALY. In the scenario analysis, the results showed that the ICERs were $263,680.69/QALY and $418,416.35/QALY when different utility values and 10-year time horizons were adopted, respectively. For PSA, the probability that amivantamab plus chemotherapy would be cost-effective was 0% if the willingness-to-pay (WTP) threshold was $150,000/QALY. Conclusion Amivantamab plus chemotherapy is unlikely to be a cost-effective option for NSCLC patients with EGFR exon 20 insertions. Reducing the cost of amivantamab may produce favorable economic outcomes.
- 11 July 2024
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 46 (6) , 1335-1344
Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States
Background Although amivantamab has shown clinical benefits for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertions, its cost-effectiveness requires further investigation. Aim To evaluate the cost-effectiveness of amivantamab plus chemotherapy for the treatment of NSCLC patients with EGFR exon 20 insertions from the United States payer perspective. Method A partitioned survival model was developed based on the data from the PAPILLON trial. Costs were derived from the pricing files of Medicare and Medicaid Services and published literature, and utility values were derived from previous studies. A 3% annual discount rate was applied to both costs and outcomes. The primary outcome was the incremental cost-effectiveness ratio (ICER). One-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis, were conducted to test the model stability. Results Amivantamab plus chemotherapy yielded an additional 1.12 quality-adjusted life years (QALYs) while increasing costs by $483,769.50 relative to the chemotherapy regimen, leading to an ICER of $432,401.16/QALY. The combination of amivantamab with chemotherapy was not cost effective at a threshold of $150,000/QALY. In the scenario analysis, the results showed that the ICERs were $263,680.69/QALY and $418,416.35/QALY when different utility values and 10-year time horizons were adopted, respectively. For PSA, the probability that amivantamab plus chemotherapy would be cost-effective was 0% if the willingness-to-pay (WTP) threshold was $150,000/QALY. Conclusion Amivantamab plus chemotherapy is unlikely to be a cost-effective option for NSCLC patients with EGFR exon 20 insertions. Reducing the cost of amivantamab may produce favorable economic outcomes.
- Open Access
Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis
Objective To evaluate the impacts of the 2017 adjustment of National Reimbursement Drug List (NRDL) on orphan drugs hospital procurement volumes and spending in China. Design We used an interrupted time series design covering the period from 2016 to 2018 to analyse changes in hospital procurement volumes and spending of orphan drugs for which were included in the 2017 NRDL. Setting and data The study was conducted in China. Orphan drug procurement data of 789 public hospitals (594 tertiary hospitals and 195 secondary hospitals) were derived from the Chinese Medical Economic Information (CMEI). Outcome measures Monthly orphan drugs hospital procurement volumes and spending. Results Nine orphan drugs were included in the 2017 NRDL (seven were directly included, and two were included after price negotiation). Comparing to orphan drugs not included in the NRDL, hospital procurement volumes ( =43 312, pConclusions Our results suggest that the 2017 adjustment of NRDL significantly changed the usage and spending on certain orphan drugs. The increase in orphan drug hospital procurement volumes should improve rare disease patients’ access to these orphan drugs.
Open AccessImpacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis
Objective To evaluate the impacts of the 2017 adjustment of National Reimbursement Drug List (NRDL) on orphan drugs hospital procurement volumes and spending in China. Design We used an interrupted time series design covering the period from 2016 to 2018 to analyse changes in hospital procurement volumes and spending of orphan drugs for which were included in the 2017 NRDL. Setting and data The study was conducted in China. Orphan drug procurement data of 789 public hospitals (594 tertiary hospitals and 195 secondary hospitals) were derived from the Chinese Medical Economic Information (CMEI). Outcome measures Monthly orphan drugs hospital procurement volumes and spending. Results Nine orphan drugs were included in the 2017 NRDL (seven were directly included, and two were included after price negotiation). Comparing to orphan drugs not included in the NRDL, hospital procurement volumes ( =43 312, pConclusions Our results suggest that the 2017 adjustment of NRDL significantly changed the usage and spending on certain orphan drugs. The increase in orphan drug hospital procurement volumes should improve rare disease patients’ access to these orphan drugs.